# Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer

> **NCT01722162** · PHASE2 · COMPLETED · sponsor: **Washington University School of Medicine** · enrollment: 47 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** Capecitabine
- **DRUG:** Levocetirizine

## Key facts

- **NCT ID:** NCT01722162
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2017-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01722162

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01722162, "Levocetirizine + Capecitabine + Bevacizumab for Patients With Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01722162. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*